CA-ESRI
20.4.2022 14:02:25 CEST | Business Wire | Press release
Capturing and sharing life's experiences today often requires multiple platforms and tools, which can result in disjointed storytelling. To serve creators' needs to control their dynamic, interactive narratives in one place, Esri , the global leader in location intelligence, today released StoryMaps, a powerful, personal storytelling tool. The product extends Esri's creative capabilities to anyone who wants to tell their story and share it.
Using Esri's mapping technology, this new software brings the geographic approach to any content that creators are passionate about. From documenting their ancestral journey to capturing aspects of daily life or planning a first big post-pandemic trip, StoryMaps helps capture life's moments in a way worthy of those experiences.
"At Esri, we understand that sharing stories is a part of life, that everyone is a storyteller," said Jack Dangermond, Esri founder and president. "Every moment and memory we treasure is connected to a specific location, which is why we're making it easier to transport people anywhere in the world through richer storytelling."
Esri allows authors to control their narratives with built-in privacy to protect data and automatic content ownership and create them in versatile ways that reflect the experiences themselves. People can creatively combine text with multimedia like images, videos, audio, and links to easily share their personal experiences, hobbies, family history, ancestry, portfolios, travels, and more.
The National Geographic Society (NGS)—which for more than 130 years has been illuminating and protecting the world through science, exploration, education, and storytelling—is partnering with Esri to bring StoryMaps to its members.
"The National Geographic Society has a long legacy of storytelling, and it remains fundamental to our mission work today as we further our understanding of our planet and each other," said Jill Tiefenthaler, National Geographic Society chief executive officer. "Our partnership with Esri enriches this legacy, empowering our members to share their unique stories and experiences through this innovative geospatial tool."
Esri designed StoryMaps to enable everyone with varying digital skills to create custom content without requiring cartography or web design experience. StoryMaps allows authors to
- Build a story in one place. Make versatile stories of any length using your assets (text, photos, videos, audio, etc.) or leverage Unsplash for ready-to-use images.
- Publish and share your story with any audience. Make a private journal, create a shareable unlisted link for family and friends, or publish on all popular social media platforms. Authors can also embed stories on websites and blogs.
- Add custom interactive maps. Bring readers along your journey by adding a map with graphics and pop-ups or create a thematic map to visualize trends.
- Incorporate engaging features. Display content in different ways using flexible components including a timeline, image gallery, swipe, and quotes. All content can be organized into collections that act like folders.
- Customize the look. Choose from built-in themes or customize a design with a different font, color, and layout options.
- Keep it current. Update and publish stories easily with new features and capabilities every two weeks. Future features will include geo-ready data from wearables to show off your latest outdoor activities.
A free basic plan is available with essential storytelling capabilities to ensure all storytellers have access at any time. When new users sign up, they have free access to Premium features with enhanced storytelling capabilities for the first 30 days. After, they can decide to purchase a monthly or annual Premium subscription to StoryMaps at $10 or $100, respectively, or downgrade to the free, basic storytelling option.
To explore StoryMaps, read stories , and get started, visit storymaps.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, StoryMaps, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005532/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom